Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast

Heba Abdel-Aziz; Olaf Kelber; Gerhard Lorkowski; Martin Storr

doi:10.1055/s-0043-116852

Planta Medica, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Planta Med 2017; 83(14/15): 1130-1140
DOI: 10.1055/s-0043-116852

Reviews

Georg Thieme Verlag KG Stuttgart · New York

Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast

Heba Abdel-Aziz

¹Phytomedicines Supply and Development Center, Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt, Germany

,

Olaf Kelber

¹Phytomedicines Supply and Development Center, Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt, Germany

,

Gerhard Lorkowski

²GL Pharma Consulting Research & Development, Gauting, Germany

,

Martin Storr

³Center of Endoscopy, Starnberg and Medical Clinic II, Ludwig-Maximilians University, Munich, Germany

› Institutsangaben

Abstract

Herbal combination preparations are widely used in traditional herbal medicine and are even established as modern evidence-based herbal medicinal products. The rationale behind such combinations is often questioned and assessing the contribution of each of the combination partners to overall activity is challenging. STW 5 (Iberogast) is such a combination with confirmed clinical efficacy in functional gastrointestinal disorders. It consists of nine plant extracts responsible for its multitarget function in these multifactorial diseases with their heterogeneous and overlapping pathomechanisms. This makes the combination an ideal candidate for the use of the newly described method of stepwise cluster analysis, a standardized procedure to transfer heterogeneous pharmacological data, from different models, into effect size categories. This allows for a stepwise cluster formation starting from the level of single tests up to the level of different pathomechanisms involved in the development of a certain disease, in this case functional dyspepsia subtypes and irritable bowel syndrome. In the current article, an overview on the pharmacological data on STW 5 and its single components is provided. The data are further analyzed using stepwise cluster formation, resulting in a summary of the different modes of action of STW 5 along with an evaluation of the contribution of the single constituents to the overall multitarget effects of the herbal combination preparation.

Key words

cluster analysis - functional dyspepsia - herbal combination preparation - irritable bowel syndrome - multitarget

Volltext

Referenzen

References
1 Allescher HD. Functional dyspepsia – a multicausal disease and its therapy. Phytomedicine 2006; 13 (Suppl. 05) 2-11
2 Rösch W, Liebregts T, Gundermann KJ, Vinson B, Holtmann G. Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW 5. Phytomedicine 2006; 13 (Suppl. 05) 114-121
3 Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology 2016; 150: 1262-1279
4 Sunderland R. Irritable bowel syndrome in adults: symptoms, treatment and management. Nurs Stand 2017; 31: 52-63
5 Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Rajilić-Stojanović M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, Spiller RC. Irritable bowel syndrome. Nat Rev Dis Primers 2016; 2: 16014
6 Schoenfeld PS. Advances in IBS 2016: A review of current and emerging data. Gastroenterol Hepatol (N Y) 2016; 12 (Suppl. 03) 1-11
7 Andresen V, Keller J, Pehl C, Schemann M, Preiss J, Layer P. Irritable bowel syndrome – the main recommendations. Dtsch Ärztebl Int 2011; 108: 751-760
8 Tack J, Talley NJ. Functional dyspepsia: symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol 2013; 10: 134-141
9 Rhee PL, Kim YH, Son HJ, Kim JJ, Koh KC, Paik SW, Rhee JC, Choi KW. The etiologic role of gastric hypersensitivity in functional dyspepsia in Korea. J Clin Gastroenterol 1999; 29: 332-335
10 Talley NJ, Walker MM, Holtmann G. Functional dyspepsia. Curr Opin Gastroenterol 2016; 32: 467-473
11 Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med 2015; 373: 1853-1863
12 Wegener T, Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogast). Phytomedicine 2006; 13 (Suppl. 05) 20-35
13 Hohenester B, Rühl A, Kelber O, Schemann M. The herbal preparation STW 5 (lberogast) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil 2004; 16: 765-773
14 Schemann M, Michel K, Zeller F, Hohenester B, Rühl A. Region-specific effects of STW 5 (Iberogast) and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13 (Suppl. 05) 90-99
15 Khayyal MT, el-Ghazaly MA, Kenawy SA, Seif-el-Nasr M, Mahran LG, Kafafi YA, Okpanyi SN. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Drug Res 2001; 51: 545-553
16 Khayyal MT, Seif-el-Nasr M, El-Ghazaly MA, Okpanyi SN, Kelber O, Weiser D. Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast) and its components against ulcers and rebound acidity. Phytomedicine 2006; 13 (Suppl. 05) 56-66
17 Beil W. In vitro Untersuchungen mit Iberogast. Study Report 13. Institut für Allgemeine Pharmakologie, Medizinische Hochschule Hannover. Darmstadt: Dokumentation Steigerwald; 1999
18 Schemann M, Angay O, Wagner S, Krueger D, Zeller F, Kelber O. Wirkung von STW 5 auf die Motilität des unteren Oesophagussphinkters und des Kolons: neue Indikationen für Iberogast. Z Gastroenterol 2008; 46: 1039 P354
19 Pilichiewicz AN, Horowitz M, Russo A, Maddox AF, Jones KL, Schemann M, Holtmann G, Feinle-Bisset C. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102: 1276-1283
20 Abdel-Aziz H, Zaki HF, Neuhuber W, Kelber O, Weiser D, Khayyal MT. Effect of an herbal preparation, STW 5, in an acute model of reflux oesophagitis in rats. J Pharmacol Sci 2010; 113: 134-142
21 Holtmann G. Talley NJ. Functional dyspepsia. Curr Opin Gastroenterol 2015; 31: 492-498
22 Abdel-Aziz H, Schneider M, Neuhuber W, Kassem AM, Khailah S, Müller J, Gamaleldeen H, Khairy A, Khayyal MT, Shcherbakova A, Efferth T, Ulrich-Merzenich G. GPR84 and TREM-1 signaling contribute to the pathogenesis of reflux esophagitis. Mol Med 2015; 21: 1011-1024
23 Michael S, Kelber O, Hauschildt S, Spanel-Borowski K, Nieber K. Inhibition of inflammation-induced alterations in rat small intestine by the herbal preparations STW 5 and STW 6. Phytomedicine 2009; 16: 161-171
24 Michael S, Abdel-Aziz H, Weiser D, Müller CE, Kelber O, Nieber K. Adenosine A(2A) receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast) in rat small intestinal preparations. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 411-421
25 Nieber K, Voß U, Abdel-Aziz H, Kelber O, Weiser D. Geschlechtsspezifische Untersuchungen zum Einfluss von STW 5 auf Entzündungsprozesse an Dickdarmpräparaten. Z Gastroenterol 2013; 51: 928 K185
26 Voß U, Michael S, Kelber O, Weiser D, Nieber K. Untersuchungen zur Wirkung von STW 5 und STW 6 auf den Tonus und die Kontraktilität an Dickdarmpräparaten Ratte. Z Gastroenterol 2011; 49: 1090 P2.136
27 Voß U, Herr F, Störmer N, Okpanyi S, Weiser D, Kelber O, Abdel-Aziz H, Nieber K. Effects of STW 5, STW 5II and their components on contractility of inflamed rat colon preparations. Young Researchers Meeting. Münster, 2012.
28 Bonaterra GA, Kinscherf R, Kelber O, Weiser D, Metz J. Antiinflammatorische und antiproliferative Wirkung von Iberogast in vitro . Z Gastroenterol 2008; 46: 1038 P352
29 Bonaterra GA, Kelber O, Weiser D, Kinscherf R. Mechanisms of the anti-proliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast) on colon adenocarcinoma (HT29) cells in vitro . Phytomedicine 2013; 20: 691-698
30 Marx L, Grundmann D, Schreiber D, Klotz M, Simon D, Rabe H, Abdel-Aziz H, Kelber O, Schäfer KH. Intestinal inflammation and motility: how does STW 5 influence this?. Z Phytother 2016; 37 (Suppl. 01) S46
31 Schneider M, Efferth T, Abdel-Aziz H. Anti-inflammatory effects of herbal preparations STW 5 and STW 5-II in cytokine-challenged normal human colon cells. Front Pharmacol 2016; 7: 393
32 Wadie W, Abdel-Aziz H, Zaki HF, Kelber O, Weiser D, Khayyal MT. STW 5 is effective in dextran sulfate sodium-induced colitis in rats. Int J Colorectal Dis 2012; 27: 1445-1453
33 Khayyal MT, Wadie W, Abdallah D, Kelber O, Abdel-Aziz H. Underlying mechanisms involved in the potential usefulness of the herbal preparation STW 5 in an experimental model of Crohnʼs disease. Planta Med 2016; 81: S1-S381
34 Schempp H, Toth A, Weiser D, Elstner EF. Mean-antioxidative properties of Iberis amara extracts in biochemical model reactions. Drug Res 2003; 53: 568-577
35 Germann I, Hagelauer D, Kelber O, Vinson B, Laufer S, Weiser D, Heinle H. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast). Phytomedicine 2006; 13 (Suppl. 05) 45-50
36 Liu CY, Müller MH, Glatzle J, Weiser D, Kelber O, Enck P, Grundy D, Kreis ME. The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 759-764
37 Müller MH, Liu CY, Glatzle J, Weiser D, Kelber O, Enck P, Grundy D, Kreis ME. STW 5 (Iberogast) reduces afferent sensitivity in the rat small intestine. Phytomedicine 2006; 13 (Suppl. 05) 100-106
38 Mittler S, Müller MH, Kasparek MS, Kelber O, Weiser D, Kreis ME. Iberis amara desensitizes colonic afferent nerve fibers in the mouse to 5-HT and low-threshold distension but not to bradykinin and high-threshold distension. Gastroenterology 2011; 140: S537
39 Simmen U, Kelber O, Okpanyi SN, Jaeggi R, Bueter B, Weiser D. Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 2006; 13 (Suppl. 05) 51-55
40 Abdel-Aziz H, Kelber O, Vinson B, Okpanyi SN, Khayyal MT. STW 5 in a model of 5-HT3 receptor mediated in vitro . Z Gastroenterol 2007; 45: 767 P079
41 Ammon HPT, Kelber O, Okpanyi SN. Spasmolytic and tonic effect of Iberogast (STW 5) in intstinal smooth muscle. Phytomedicine 2006; 13 (Suppl. 05) 67-74
42 Voß U, Michael S, Kelber O, Weiser D, Nieber K. Vergleichende Untersuchungen zur Wirkung von STW 5 und STW 6 auf den Tonus und die Kontraktilität an Dünn- und Dickdarmpräparaten Ratte. Z Gastroenterol 2010; 48: 955 P265
43 Allam S. Actions of the phytopharmacon Iberogast in different regions of the gut [dissertation]. Munich: Technical University; 2014
44 Sibaev A, Abdel-Aziz H, Kelber O, Allescher HD, Storr M. Mechanism of action of STW 5 and its components on motility and intestinal neurotransmission in “in vitro” model of the human colon. Neurogastroenterol Motil 2015; 27 (Suppl. 02) 101
45 Allam S, Krueger D, Demir IE, Ceyhan G, Zeller F, Schemann M. Extracts from peppermint leaves, lemon balm leaves and in particular angelica roots mimic the pro-secretory action of the herbal preparation STW 5 in the human intestine. Phytomedicine 2015; 22: 1063-1070
46 Lee KJ, Tack J. Duodenal implications in the pathophysiology of functional dyspepsia. J Neurogastroenterol Motil 2010; 16: 251-257

Zusatzmaterial

Supporting Information